How to Buy Biomarin Pharmaceutical Stock
Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Biomarin Pharmaceutical stock last closed at $51.84, down 0.73% from the previous day, and has decreased 23.13% in one year. It has overperformed other stocks in the Biotechnology industry by 0.36 percentage points. Biomarin Pharmaceutical stock is currently +1.65% from its 52-week low of $51.00, and -29.48% from its 52-week high of $73.51.
At the moment, there are 192.11M shares of BMRN outstanding. The market value of BMRN is $9.96B. In the last 24 hours, 2.96M BMRN shares were traded.
How to Buy Biomarin Pharmaceutical Stock
Not sure how to invest in Biomarin Pharmaceutical stock? Here's how.
- Choose where to buy Biomarin Pharmaceutical stock: You need to pick an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you determine where to buy Biomarin Pharmaceutical stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Put funds into your investment account: Select your payment method and add your details.
- Research Biomarin Pharmaceutical stock: The Biomarin Pharmaceutical ticker symbol is BMRN. Is Biomarin Pharmaceutical stock a good investment? Should you buy shares of BMRN? How do BMRN's underlying business fundamentals look? Do top analysts think Biomarin Pharmaceutical is a good buy? Why has BMRN's stock price moved recently? (Hint: Our stock research tools can help you decide if BMRN is a good stock to buy).
- Make your BMRN buy order: Decide if you will purchase BMRN shares at the current market price or use a limit order to buy BMRN shares at a given price.
- Get notifications regarding your BMRN investment: Create a watchlist to important notifications about your new investment in Biomarin Pharmaceutical shares.
Step 1: Choose where to buy Biomarin Pharmaceutical stock
You need an online brokerage account in order to access the NASDAQ market and buy BMRN stock.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to global markets: From Technology to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal info so you are able to buy BMRN stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to open a new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've created your account on apps for stock market, your next step is to transfer the money for your investment:
Check out the walkthrough below if you need help transferring money into your investment account.
Step 4: Research Biomarin Pharmaceutical stock
Once you have decided on the best place to buy Biomarin Pharmaceutical stock, it's absolutely critical to research their stock prior to investing, so you actually understand the risk as well as the upside.
Biomarin Pharmaceutical Metrics
Biomarin Pharmaceutical Fundamentals
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on BMRN's stock page.
Is BMRN stock undervalued or overvalued?
You can use many financial metrics, analyses, models, and charts to gauge BMRN's intrinsic value.
Using relative valuations ratios:
- BMRN may be undervalued based on its P/E ratio of 19.06x, relative to Biotechnology industry P/E ratio of 252.41x
- BMRN could be undervalued based on its P/B ratio of 1.64x, relative to Biotechnology industry P/B ratio of 4.85x
- BMRN could be undervalued based on its PEG ratio of 0.74x
You can do additional valuation research on BMRN's stock here.
How do BMRN Financials look?
Pros:
- BMRN's operating cash flow of $913.98M allows it to safely service it's debt of $596.66M.
- BMRN profit margin has gone up from 11.7% to 16.8% in the past year.
- There are more short-term assets than long-term liabilities on the BMRN balance sheet.
- BMRN earnings of $689.97M is not enough to cover its interest payments.
- There are more short-term assets than short-term liabilities on the BMRN balance sheet.
- Total BMRN debt is lower than 5 years ago, relative to shareholder equity.
- BMRN has a low debt to equity ratio of 0.26.
Is it a good time to buy Biomarin Pharmaceutical stock, according to analysts?
Out of 10 Equities analysts who give recommendations on BMRN, the consensus analyst rating on BMRN is a Strong Buy
It's important to keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Latest BMRN Analyst Upgrades/Downgrades
Matthew Harrison, a top 23% analyst from Morgan Stanley maintains BMRN with a strong buy rating and lowers their BMRN price target from $104.00 to $98.00, on Oct 28, 2025.
Morgan Stanley's Matthew Harrison lowered their price target on Biomarin Pharmaceutical (NASDAQ: BMRN) by 5.8% from $104 to $98 on 2025/10/28. The analyst maintained their Strong Buy rating on the stock.
BioMarin Pharmaceutical reported its Q3 2025 earnings.
Cutting their price target, Harrison highlighted that management rescinded its FY 2027 guidance, previously set at $4B, because of potential competition from Ascendis TransCon CNP, and suggested revenge closer to the $3.65B consensus.
The analyst argued that a competitor to Voxzogo must launch before investors become constructive on the stock.
That said, however, Harrsion said that the stock "appears a compelling value" in the context of Street forecasts and the company's balance sheet capacity.
Earnings Report
For Q3 2025, BioMarin Pharmaceutical reported:
- EPS of $0.12, which beat the Zacks Consensus Estimate of $(0.15) but missed Q3 2024's $0.91.
- Revenue of $776.13M, which missed the Zacks Consensus Estimate by 1.05% but beat Q3 2024's $745.74.
For FY 2025, management guided:
- EPS of $3.50 to $3.60, down from the prior $4.40 to $4.55.
- Revenue of $3.15B to $3.2B, narrowed from the prior $3.125B to $3.2B.
President & CEO Alexander Hardy commented: “We are pleased with the contributions from our Enzyme Therapies and Skeletal Conditions business units to date this year driven by more than 20% revenue growth from PALYNZIQ and VOXZOGO.
"Our strategic investments in these focused business units are generating strong results, and we anticipate sustained financial performance from each of them.
"Both Enzyme Therapies and Skeletal Conditions remain central to our growth strategy, in addition to new business development opportunities and our advancing internal pipeline.
"As we focus on the business units aligned with our strategic priorities, today we are announcing the decision to pursue options to divest ROCTAVIAN and remove it from our portfolio.
"We continue to believe ROCTAVIAN has an important role to play in the treatment of hemophilia A and are therefore evaluating out-licensing options for this innovative gene therapy.
"This decision is consistent with BioMarin’s portfolio strategy and offers the most promising opportunity for ensuring continued patient access to ROCTAVIAN.
“Looking ahead, we will rely on our disciplined strategic focus and proven capabilities to develop and commercialize innovative therapies that generate sustainable value for patients, employees, and shareholders."
Mitchell S. Kapoor, a top 30% analyst from HC Wainwright & Co. maintains BMRN with a hold rating and lowers their BMRN price target from $60.00 to $55.00, on Oct 27, 2025.
Jessica Fye, a top 4% analyst from JP Morgan maintains BMRN with a strong buy rating and raises their BMRN price target from $116.00 to $119.00, on Oct 9, 2025.
Debjit Chattopadhyay, a top 14% analyst from Guggenheim maintains BMRN with a strong buy rating and raises their BMRN price target from $101.00 to $106.00, on Aug 6, 2025.
Eliana Merle, a top 16% analyst from UBS maintains BMRN with a strong buy rating and raises their BMRN price target from $113.00 to $114.00, on Aug 5, 2025.
You can dive deeper into what analysts are saying on the Biomarin Pharmaceutical stock forecast page.
BMRN Technicals
Is BMRN Making Money?
Last year, BMRN earnings were $520.42M. Over the past 5 year, BMRN's earnings have gone up by -10.4% per year. This was slower than the Biotechnology industry average of 8.83%.
Last year, BMRN revenue was $3.09B. In the past five year, BMRN's revenue has gone up by 10.68% per year. This was slower than the Biotechnology industry average of 53.59%.
You can analyze BMRN's earnings and revenue performance here.
Latest Insiders Trades at BMRN
In the past 12 months, executives and large shareholders at BMRN have sold more shares than they have bought.
Gregory R. Friberg, EVP Chief RD Officer of BMRN, was the latest BMRN insider to sell. They sold $178,944.64 worth of BMRN stock on Sep 30, 2025.
Dig into more about who owns BMRN shares here.
Can I get consistent income from BMRN stock?
No, Biomarin Pharmaceutical doesn't provide an income stream by paying out dividends.
What do other investors have to say about BMRN?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your BMRN buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly fine for most investors. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a given price, place a limit order.
Click the Open Trade button and your broker will place your order.
If you need additional help with buying stocks on eToro, click the helpful video below:
Step 6: Get notifications regarding your BMRN investment
Now that you own some BMRN shares, you'll want to keep up with your new investment.
Start a watchlist to track your BMRN stock.
BMRN Feed
How to Buy Stock in Biomarin Pharmaceutical
To summarize, here are the 6 steps to buy Biomarin Pharmaceutical stock:
- Choose where to buy Biomarin Pharmaceutical stock
- Open your brokerage account
- Put funds into your investment account
- Research Biomarin Pharmaceutical stock
- Make your BMRN buy order
- Get notifications regarding your BMRN investment
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your new investment in Biomarin Pharmaceutical, create a watchlist on WallStreetZen today.
Other Articles You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.